Biologics CDMO Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Biologics CDMO Market Report is Segmented by Service Type (Process Development, GMP Manufacturing, and More), Type (Mammalian, Microbial), Product Type (Biologics [Monoclonal Antibodies, Recombinant Proteins, and More], Biosimilars), Scale (Pre-Clinical and Clinical, Commercial), End-User (Small/Mid-size Biotech, Large Pharma), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Biologics CDMO Market Size and Share

Biologics CDMO Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Biologics CDMO Market with other markets in Packaging Industry

Biologics CDMO Market Analysis by Mordor Intelligence

The biologics CDMO market size reached a value of USD 25.32 billion in 2025 and is forecast to attain USD 36.51 billion by 2030, advancing at a 7.59% CAGR during 2025-2030. Robust demand for outsourced capacity, rising complexity of next-generation therapeutics, and mounting capital requirements for in-house facilities continue to steer sponsors toward specialized partners. Uptake of continuous manufacturing and single-use technologies is lifting operational agility, while full-service providers are broadening analytical, regulatory, and fill-finish offerings to capture a larger share of the biologics CDMO market. Expansionary moves—such as Samsung Biologics’ 2024 achievement of full utilization across 362,000 L of bioreactors and Lonza’s USD 1.2 billion acquisition of Genentech’s Vacaville plant—signal tightening global capacity and intensifying competition. Regional dynamics add another growth layer: North America leads on revenue, but Asia-Pacific is posting the fastest gains thanks to pro-manufacturing policy incentives in China, South Korea, and India.

Key Report Takeaways

  • By service type, fill-finish and packaging led with 35.32% biologics CDMO market share in 2024; analytical and QC services are projected to expand at a 12.43% CAGR through 2030.
  • By type , mammalian systems held 62.32% of biologics CDMO market size in 2024; microbial systems are forecast to grow at an 8.56% CAGR.
  • By product Type, biologics commanded 68.32% revenue share in 2024, while biosimilars are advancing at a 9.04% CAGR to 2030.
  • By scale, commercial manufacturing accounted for 55.64% of biologics CDMO market size in 2024; pre-clinical and clinical production is rising at an 8.53% CAGR.
  • By end-user, large pharma controlled 56.43% share in 2024; SME biotech is set to expand at an 8.68% CAGR through 2030.
  • By geography, North America controlled 34.54% share in 2024; Asia-Pacific is set to expand at an 10.76% CAGR through 2030.

Segment Analysis

By Service Type: Fill-Finish Dominance Drives Integrated Solutions

Fill-finish and packaging services captured 35.32% biologics CDMO market share in 2024, underlining the sterility and regulatory stakes of final drug-product preparation. Growth is reinforced by big-ticket investments such as Lonza’s CHF 500 million Swiss facility. Parallel demand for robust release testing is accelerating analytical and QC uptake, which is projected to post a 12.43% CAGR through 2030.

Integrated developers increasingly bundle process development, GMP production, analytical, and regulatory support to minimize hand-offs. Eurofins BioPharma’s network of 45 GMP labs exemplifies the trend toward geographically diversified, full-scope testing that shortens release cycles. This integrative model embeds stickier relationships and positions suppliers to harvest incremental share of the biologics CDMO market.

Biologics CDMO Market: Market Share by Service Type
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Type: Mammalian Systems Lead Amid Microbial Expansion

Mammalian platforms generated 62.32% of biologics CDMO market size in 2024, reflecting their necessity for monoclonal antibodies and other glycosylation-dependent drugs. Samsung’s scale-up to 784,000 L underscores continued investment in high-titer CHO production.

Microbial systems are advancing on an 8.56% CAGR tailwind owing to simplified process trains and cost advantages. Thermo Fisher’s single-use fermentors reduce contamination risk and shorten turnovers, broadening microbial applicability to peptide and oligonucleotide therapeutics. The resulting flexibility attracts emerging sponsors seeking economical early-stage production.

By Product Type: Biologics Maintain Leadership Amid Biosimilar Uptick

Innovator biologics remained the mainstay at 68.32% of 2024 revenue, buoyed by a vibrant pipeline of antibody-drug conjugates, multispecific antibodies, and RNA-based constructs. Samsung’s S-AfucHO and S-OptiCharge platforms target improved efficacy and downstream yields, fortifying competitive position.

Biosimilars, while smaller, are gaining velocity at 9.04% CAGR as payers push affordability and patents expire. Streamlined EMA pathways introduced in 2024 lower entry barriers, prompting established CDMOs to launch dedicated biosimilar suites to win contracts from cost-sensitive sponsors.

By Scale: Commercial Manufacturing Commands Majority Share

Commercial lots accounted for 55.64% of biologics CDMO market size in 2024, mirroring portfolio maturation of launched therapeutics. Mega-plants exceeding 10,000 L remain critical for blockbuster antibodies and high-volume insulin analogs.

Clinical and pre-clinical projects are rising steadily on an 8.53% CAGR, fueled by a record 25% jump in 2024 IND filings for biologics. Flexible multi-product suites with rapid changeover capability are therefore a pivotal differentiator for CDMOs courting pipeline-heavy biotech clients.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By End-user: Large Pharma Dominance Balanced by SME Momentum

Large pharmaceutical firms utilized CDMOs for 56.43% of outsourced spend in 2024, leveraging long-term contracts to secure redundant supply while divesting non-core assets such as Roche’s Vacaville site.

SME biotechs, expanding at an 8.68% CAGR, increasingly rely on end-to-end CRDMO platforms to bridge expertise gaps and improve capital efficiency. Their growth ensures a steady influx of early-stage work that underpins long-run expansion of the biologics CDMO market.

Geography Analysis

North America retained leadership with 34.54% of 2024 revenue, propelled by dense innovation ecosystems and regulatory support for advanced manufacturing. FDA guidance on continuous processing and expedited review pathways fosters early adoption curves that benefit local CDMOs. Large-scale investments such as Novo Nordisk’s USD 4.1 billion North Carolina plant reinforce the region’s installed base.

Europe offers a sophisticated framework dominated by Germany, the United Kingdom, and Switzerland. Lonza’s CHF 500 million fill-finish hub in Stein exemplifies the continent’s specialized, high-margin focus. Updated EMA biologics guidelines simplify technology transfers and sustain steady inflows of both domestic and trans-Atlantic work. Emerging projects—such as Biosynth’s German bioconjugation expansion—underscore persistent demand for niche expertise.

Asia-Pacific is the growth engine, set to post a 10.76% CAGR through 2030 on the back of aggressive capacity builds and public-sector incentives. Samsung Biologics’ expansion to 784,000 L and SK pharmteco’s USD 260 million Sejong project typify South Korea’s strategy to become a global biologics powerhouse. China’s streamlined NMPA approval procedures and India’s infrastructure grants are equally pivotal in channeling sponsor projects into the region.

Biologics CDMO Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The biologics CDMO market is fragmented. Novo Holdings’ USD 16.5 billion Catalent deal and Lonza’s Vacaville purchase alter global capacity distribution and intensify the fight for large-scale antibody contracts. Samsung Biologics, now running at full utilization, signals that top-tier suppliers hold valuable pricing power supported by differentiated scale.

Technology is the linchpin of competitive edge. FUJIFILM Diosynth’s MaruX continuous line and Lonza’s Ibex bioconjugation suites cater to high-growth modalities, enabling premium service rates. Simultaneously, integrated CRDMO models are surfacing as a preferred one-stop solution for SMEs, creating a bifurcated field where scale leaders and niche specialists coexist.

Strategic collaborations illustrate market dynamism: BioCina’s merger with NovaCina blends microbial, mRNA, and sterile fill-finish capabilities to form a vertically integrated challenger. Such moves highlight sustained competition for wallet share across every stage of the biologics CDMO market value chain.

Biologics CDMO Industry Leaders

  1. Boehringer Ingelheim Group

  2. Wuxi Biologics (Cayman) Inc.

  3. Samsung Biologics

  4. Lonza Group Ltd

  5. Fujifilm Diosynth Biotechnologies USA Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Biologics Contract Development & Manufacturing Organization (CDMO) Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • February 2025: BioCina and NovaCina completed a merger to build an end-to-end global CDMO under CEO Mark W. Womack.
  • February 2025: WuXi Biologics partnered with Candid Therapeutics in a USD 925 million trispecific T-cell engager agreement.
  • February 2025: SK pharmteco announced a USD 260 million Sejong facility for small-molecule and peptide production.
  • November 2024: Avid Bioservices accepted a USD 1.1 billion take-private offer from GHO and Ampersand

Table of Contents for Biologics CDMO Industry Report

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET LANDSCAPE

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Aging population and chronic-disease pipeline expansion
    • 4.2.2 Capital-intensive biologics innovation driving outsourcing
    • 4.2.3 SME biotech preference for asset-light CDMO partnerships
    • 4.2.4 Continuous bioprocessing accelerates flexible capacity
    • 4.2.5 Single-use technologies compress CAPEX and timelines
    • 4.2.6 Cell and gene therapy manufacturing spill-over to biologics CDMOs
  • 4.3 Market Restraints
    • 4.3.1 Evolving global GMP and comparability requirements
    • 4.3.2 Persistent capacity bottlenecks lengthen lead-times
    • 4.3.3 Captive facility expansion by big pharma reduces outsourcing
    • 4.3.4 Resin and single-use component supply fragility
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Bargaining Power of Suppliers
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Threat of New Entrants
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. MARKET SIZE AND GROWTH FORECASTS (VALUE)

  • 5.1 By Service Type
    • 5.1.1 Process Development
    • 5.1.2 GMP Manufacturing
    • 5.1.3 Fill-Finish and Packaging
    • 5.1.4 Analytical and QC Services
    • 5.1.5 Other Service Type
  • 5.2 By Type
    • 5.2.1 Mammalian
    • 5.2.2 Microbial
  • 5.3 By Product Type
    • 5.3.1 Biologics
    • 5.3.1.1 Monoclonal Antibodies
    • 5.3.1.2 Recombinant Proteins
    • 5.3.1.3 Vaccines
    • 5.3.1.4 Antisense / Molecular Therapy
    • 5.3.1.5 Other Biologics
    • 5.3.2 Biosimilars
  • 5.4 By Scale
    • 5.4.1 Pre-clinical and Clinical
    • 5.4.2 Commercial
  • 5.5 By End-user
    • 5.5.1 Small / Mid-size Biotech
    • 5.5.2 Large Pharma
  • 5.6 By Geography
    • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
    • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Russia
    • 5.6.2.7 Rest of Europe
    • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia and New Zealand
    • 5.6.3.6 Rest of Asia-Pacific
    • 5.6.4 Middle East and Africa
    • 5.6.4.1 Middle East
    • 5.6.4.1.1 United Arab Emirates
    • 5.6.4.1.2 Saudi Arabia
    • 5.6.4.1.3 Turkey
    • 5.6.4.1.4 Rest of Middle East
    • 5.6.4.2 Africa
    • 5.6.4.2.1 South Africa
    • 5.6.4.2.2 Nigeria
    • 5.6.4.2.3 Egypt
    • 5.6.4.2.4 Rest of Africa
    • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Market Concentration
  • 6.2 Strategic Moves
  • 6.3 Market Share Analysis
  • 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
    • 6.4.1 Lonza Group
    • 6.4.2 Samsung Biologics
    • 6.4.3 WuXi Biologics
    • 6.4.4 Boehringer Ingelheim BioXcellence
    • 6.4.5 Catalent
    • 6.4.6 Fujifilm Diosynth Biotechnologies
    • 6.4.7 AGC Biologics
    • 6.4.8 Thermo Fisher Scientific (Patheon)
    • 6.4.9 AbbVie Contract Manufacturing
    • 6.4.10 Rentschler Biopharma
    • 6.4.11 Celonic
    • 6.4.12 Binex
    • 6.4.13 Sandoz
    • 6.4.14 Parexel
    • 6.4.15 ICON plc
    • 6.4.16 Recipharm – Arranta Bio
    • 6.4.17 Toyobo
    • 6.4.18 Emergent BioSolutions CDMO
    • 6.4.19 Porton Biologics
    • 6.4.20 Just-Evotec Biologics
    • 6.4.21 Grifols Contract Manufacturing

7. MARKET OPPORTUNITIES AND FUTURE OUTLOOK

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Biologics CDMO Market Report Scope

A biologics contract development and manufacturing organization (CDMO) is a third-party company that helps pharmaceutical companies develop and manufacture biological drugs. CDMOs can help with research, development, manufacturing, and more. The research also examines underlying growth influencers and significant industry vendors, all of which help to support market estimates and growth rates throughout the anticipated period. The market estimates and projections are based on the base year factors and arrived at top-down and bottom-up approaches.

The biologics contract development and manufacturing organization (CDMO) market is segmented by type (Mammalian and Non-Mammalian (Microbial)), by product type (biologics [monoclonal, recombinant proteins, antisense, and molecular therapy, vaccines, and other biologics], and biosimilars), by geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The market sizes and forecasts are provided in terms of value in USD for all the above segments.

By Service Type Process Development
GMP Manufacturing
Fill-Finish and Packaging
Analytical and QC Services
Other Service Type
By Type Mammalian
Microbial
By Product Type Biologics Monoclonal Antibodies
Recombinant Proteins
Vaccines
Antisense / Molecular Therapy
Other Biologics
Biosimilars
By Scale Pre-clinical and Clinical
Commercial
By End-user Small / Mid-size Biotech
Large Pharma
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Russia
Rest of Europe
Asia-Pacific China
India
Japan
South Korea
Australia and New Zealand
Rest of Asia-Pacific
Middle East and Africa Middle East United Arab Emirates
Saudi Arabia
Turkey
Rest of Middle East
Africa South Africa
Nigeria
Egypt
Rest of Africa
South America Brazil
Argentina
Rest of South America
By Service Type
Process Development
GMP Manufacturing
Fill-Finish and Packaging
Analytical and QC Services
Other Service Type
By Type
Mammalian
Microbial
By Product Type
Biologics Monoclonal Antibodies
Recombinant Proteins
Vaccines
Antisense / Molecular Therapy
Other Biologics
Biosimilars
By Scale
Pre-clinical and Clinical
Commercial
By End-user
Small / Mid-size Biotech
Large Pharma
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Russia
Rest of Europe
Asia-Pacific China
India
Japan
South Korea
Australia and New Zealand
Rest of Asia-Pacific
Middle East and Africa Middle East United Arab Emirates
Saudi Arabia
Turkey
Rest of Middle East
Africa South Africa
Nigeria
Egypt
Rest of Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the biologics CDMO market?

The biologics CDMO market is valued at USD 25.32 billion in 2025 and is projected to hit USD 36.51 billion by 2030.

Which service segment holds the largest share?

Fill-finish and packaging services led with 35.32% biologics CDMO market share in 2024.

Which region is growing fastest?

Asia-Pacific is forecast to expand at a 10.76% CAGR through 2030, outpacing all other regions.

Why are SME biotech firms turning to CDMOs?

Asset-light outsourcing lets SMEs cut time-to-market by around 40% and preserve capital for R&D activities.

How is continuous manufacturing affecting CDMO strategies?

Continuous bioprocessing cuts cycle times by up to 50%, prompting CDMOs to invest in new lines that boost flexibility and lower operating costs.

What factors limit market growth?

Evolving global GMP standards, component supply fragility, and rising internal capacity at large pharma companies are key restraints.

Page last updated on: July 10, 2025

Biologics CDMO Market Report Snapshots